Abstract
Thirty patients with previously treated metastatic breast cancer were entered in a phase II study with oral lonidamine. Twenty-eight patients are evaluable for toxicity and 25 for response. A partial remission was obtained in four patients (16%) and disease stability in 11 (44%): 10 patients progressed (40%). Toxicity was acceptable, consisting mainly of myalgias (39% of patients) and asthenia (21.4%). No myelotoxicity was observed. The drug is active in previously treated metastatic breast cancer and, because of its peculiar pattern of action and toxicity, deserves to be evaluated in combination with cytotoxic chemotherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pronzato, P., Amoroso, D., Bertelli, G. et al. Phase II study of lonidamine in metastatic breast cancer. Br J Cancer 59, 251–253 (1989). https://doi.org/10.1038/bjc.1989.51
Issue Date:
DOI: https://doi.org/10.1038/bjc.1989.51
This article is cited by
-
Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer
Breast Cancer Research and Treatment (1995)
-
Relative cytotoxicities of Adriamycin and epirubicin in combination with lonidamine against human bladder cancer cell lines
Urological Research (1995)
